Targeting HIF‐1α with Specific DNA Yokes for Effective Anticancer Therapy

Abstract

Hypoxia, a ubiquitous hallmark in cancer, underscores the significance of targeting HIF‐1α, the principal transcriptional factor of hypoxic responses, for effective cancer therapy. Herein, we introduce DNA yokes, a novel class of DNA nanomaterials harboring specific HIF‐1α binding sequences (hypoxia response elements, HREs), as nano‐pharmaceuticals for cancer treatment. Comprising a basal tetrahedral DNA nanostructure (TDN) and four HRE‐bearing overhanging chains, DNA yokes exhibit exceptional stability and prolonged intracellular retention. Our investigation reveals their capacity to bind HIF‐1α, thereby disrupting its interaction with the downstream genomic DNAs and impeding transcriptional activity. Moreover, DNA yokes facilitate HIF‐1α degradation via the ubiquitination pathway, thereby sequestering it from downstream targets and ultimately promoting its degradation. Additionally, DNA yokes attenuate cancer cell proliferation, migration, and invasion under hypoxic conditions, while also displaying preferential accumulation within tumors, thereby inhibiting tumor growth and metastasis in vivo. This study pioneers a novel approach to cancer therapy through the development of DNA‐based drugs characterized by high stability and low toxicity to normal cells, positioning DNA yokes as promising candidates for cancer treatment.This article is protected by copyright. All rights reserved